T-cell non-Hodgkin lymphoma. 2006

Mujahid A Rizvi, and Andrew M Evens, and Martin S Tallman, and Beverly P Nelson, and Steven T Rosen
Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 N St Clair St, Ste 850, Chicago, IL 60611, USA. m-rizvi@md.northwestern.edu

T-cell non-Hodgkin lymphomas (NHLs) are uncommon malignancies. The current WHO/EORTC classification recognizes 9 distinct clinicopathologic peripheral T-cell NHLs. These disorders have unique characteristics and require individualized diagnostic and therapeutic strategies. Tremendous progress has been made in recent years in the understanding of the pathogenesis of these disorders. Specific chromosomal translocations and viral infections are now known to be associated with certain lymphomas. In this review, we describe their clinical and pathologic features. We also discuss the use of molecular studies in the diagnostic work-up of T-cell lymphomas. Because of the rarity of these disorders and the lack of well-designed clinical trials, the treatment of peripheral T-cell NHLs is often challenging. Additional studies are required to learn more about the biology of these diseases, which may lead to more optimal and possibly targeted therapies.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D014178 Translocation, Genetic A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome. Chromosomal Translocation,Translocation, Chromosomal,Chromosomal Translocations,Genetic Translocation,Genetic Translocations,Translocations, Chromosomal,Translocations, Genetic
D016399 Lymphoma, T-Cell A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes. T-Cell Lymphoma,Lymphoma, T Cell,Lymphomas, T-Cell,T Cell Lymphoma,T-Cell Lymphomas
D016410 Lymphoma, T-Cell, Cutaneous A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders. Granulomatous Slack Skin,T-Cell Lymphoma, Cutaneous,Cutaneous T-Cell Lymphoma,Lymphoma, T Cell, Cutaneous,Cutaneous T Cell Lymphoma,Cutaneous T-Cell Lymphomas,Lymphoma, Cutaneous T-Cell,Lymphomas, Cutaneous T-Cell,Slack Skin, Granulomatous,T Cell Lymphoma, Cutaneous,T-Cell Lymphomas, Cutaneous

Related Publications

Mujahid A Rizvi, and Andrew M Evens, and Martin S Tallman, and Beverly P Nelson, and Steven T Rosen
January 2008, JBR-BTR : organe de la Societe royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR),
Mujahid A Rizvi, and Andrew M Evens, and Martin S Tallman, and Beverly P Nelson, and Steven T Rosen
September 2016, Lancet (London, England),
Mujahid A Rizvi, and Andrew M Evens, and Martin S Tallman, and Beverly P Nelson, and Steven T Rosen
February 2019, Oncology (Williston Park, N.Y.),
Mujahid A Rizvi, and Andrew M Evens, and Martin S Tallman, and Beverly P Nelson, and Steven T Rosen
January 2013, Anais brasileiros de dermatologia,
Mujahid A Rizvi, and Andrew M Evens, and Martin S Tallman, and Beverly P Nelson, and Steven T Rosen
January 2015, Case reports in obstetrics and gynecology,
Mujahid A Rizvi, and Andrew M Evens, and Martin S Tallman, and Beverly P Nelson, and Steven T Rosen
March 2013, Blood,
Mujahid A Rizvi, and Andrew M Evens, and Martin S Tallman, and Beverly P Nelson, and Steven T Rosen
September 2008, Clinical advances in hematology & oncology : H&O,
Mujahid A Rizvi, and Andrew M Evens, and Martin S Tallman, and Beverly P Nelson, and Steven T Rosen
September 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Mujahid A Rizvi, and Andrew M Evens, and Martin S Tallman, and Beverly P Nelson, and Steven T Rosen
May 2018, Current research in translational medicine,
Mujahid A Rizvi, and Andrew M Evens, and Martin S Tallman, and Beverly P Nelson, and Steven T Rosen
January 2012, Ear, nose, & throat journal,
Copied contents to your clipboard!